Is CG a buy, hold, or sell?
CG carries a valuation grade of Hold. The trailing P/E of 30.2 sits 116% above the Financials sector median of 14.0x — a premium that demands sustained earnings delivery. Our discounted cash flow model produces an intrinsic range of $42–$73 — implying a +28% margin of safety at the current price of $45.14. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 6% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter missed by a 2.8% earnings surprise. Analyst estimate revisions are trending upward.
What are CG's key risk factors?
With a beta of 1.82, CG exhibits a highly aggressive risk profile relative to the broad market. The 95th-percentile CVaR of -20.4% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 2.0% of total portfolio loss in the worst 5% of months. Net margins of 16.8% fall below the Financials sector average of 28%, suggesting margin pressure. Leverage is moderate with debt-to-equity at 198%.
Insiders have been net sellers to the tune of $116.1M recently. While routine dispositions are common, the magnitude bears watching. Short interest stands at 5.9% of float, a moderate level.
How does CG fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — CG carries a beta of 1.82, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, CG shows the strongest co-movement with KKR (0.76), BX (0.75), ARES (0.69). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios. With the top peer correlation at 0.76, adding CG to a portfolio that already holds these names provides limited marginal diversification benefit — particularly during stress events when correlations converge toward 1.0.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The CG analysis here is a single node in that larger structure.
For our full conviction hierarchy across alternative asset managers — including CG's positioning in the 2026 private credit stress test — see: Private Equity 2026: $265B Crisis — Why Blackstone & KKR Lead. For the BDC redemption mechanics and fund-level data underpinning these ratings: Private Credit 2026: BDC Liquidity Crisis & Systemic Stress Test →
